Barclays PLC Sells 102,720 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Barclays PLC decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 24.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 319,589 shares of the biotechnology company’s stock after selling 102,720 shares during the period. Barclays PLC owned 0.11% of Exelixis worth $8,294,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in EXEL. Farallon Capital Management LLC increased its position in Exelixis by 1.6% during the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after buying an additional 424,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Exelixis by 0.4% in the second quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock worth $340,714,000 after acquiring an additional 61,350 shares during the last quarter. LSV Asset Management increased its holdings in shares of Exelixis by 107.7% during the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after acquiring an additional 2,989,021 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Exelixis by 7.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock worth $115,434,000 after purchasing an additional 349,837 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in Exelixis by 12.7% in the 2nd quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock worth $73,425,000 after purchasing an additional 370,199 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Wells Fargo & Company lifted their target price on shares of Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. BMO Capital Markets increased their price objective on Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Morgan Stanley boosted their target price on shares of Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, October 11th. Guggenheim lifted their price objective on shares of Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Finally, UBS Group initiated coverage on Exelixis in a research report on Thursday, September 19th. They set a “neutral” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $31.88.

Exelixis Stock Performance

NASDAQ:EXEL opened at $34.69 on Wednesday. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $36.97. The company’s 50-day simple moving average is $33.04 and its 200-day simple moving average is $27.38. The stock has a market capitalization of $9.91 billion, a P/E ratio of 22.24, a P/E/G ratio of 0.89 and a beta of 0.52.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. During the same period in the prior year, the firm posted $0.10 earnings per share. The business’s quarterly revenue was up 14.3% on a year-over-year basis. On average, research analysts forecast that Exelixis, Inc. will post 1.69 EPS for the current year.

Insider Transactions at Exelixis

In related news, EVP Jeffrey Hessekiel sold 60,000 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the transaction, the executive vice president now owns 486,059 shares in the company, valued at approximately $17,823,783.53. This represents a 10.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Dana Aftab sold 1,162 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the sale, the executive vice president now owns 498,945 shares in the company, valued at $15,666,873. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 339,736 shares of company stock worth $11,508,610. Insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.